Takeda Pharmaceutical Crescita futura

Future criteri di controllo 1/6

Takeda Pharmaceutical prevede che gli utili e i ricavi cresceranno rispettivamente di 12.2% e 0.9% all'anno. Si prevede che l'EPS crescerà di 12.4% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 4.1% in 3 anni.

Informazioni chiave

12.2%

Tasso di crescita degli utili

12.4%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	24.0%
Tasso di crescita dei ricavi	0.9%
Rendimento futuro del capitale proprio	4.1%
Copertura analitica	Good
Ultimo aggiornamento	02 Dec 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Takeda Pharmaceuticals: An Interesting Option For Income Investors

Oct 07

Takeda: Strong Growth Catalysts And Maturing Pipeline Continue To Limit Downside Risk

Jun 06

Previsioni di crescita degli utili e dei ricavi

NYSE:TAK - Stime future degli analisti e dati finanziari passati (JPY Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
3/31/2027	4,572,132	292,086	675,690	974,751	16
3/31/2026	4,513,367	226,193	687,713	951,887	17
3/31/2025	4,476,556	111,441	409,238	820,630	17
9/30/2024	4,546,083	289,996	536,390	876,306	N/A
6/30/2024	4,413,134	149,920	444,957	794,248	N/A
3/31/2024	4,263,762	144,067	235,614	716,344	N/A
12/31/2023	4,169,049	178,219	-129,035	731,449	N/A
9/30/2023	4,154,414	191,626	129,243	963,227	N/A
6/30/2023	4,113,631	301,398	180,765	985,315	N/A
3/31/2023	4,027,478	317,017	343,467	977,156	N/A
12/31/2022	3,944,611	274,525	817,615	1,059,047	N/A
9/30/2022	3,749,354	213,167	789,089	1,028,328	N/A
6/30/2022	3,591,868	197,389	798,367	1,040,488	N/A
3/31/2022	3,569,006	230,059	937,068	1,123,105	N/A
12/31/2021	3,465,991	438,515	902,309	1,148,481	N/A
9/30/2021	3,401,450	473,105	777,572	1,018,931	N/A
6/30/2021	3,345,565	431,178	793,645	1,031,928	N/A
3/31/2021	3,197,812	376,005	774,463	1,010,931	N/A
12/31/2020	3,199,240	180,631	608,015	795,408	N/A
9/30/2020	3,221,804	56,051	498,511	720,676	N/A
6/30/2020	3,243,917	119,743	479,618	694,824	N/A
3/31/2020	3,291,188	44,241	452,042	669,752	N/A
12/31/2019	3,236,697	13,275	402,421	601,798	N/A
9/30/2019	2,876,782	83,262	399,600	551,732	N/A
6/30/2019	2,496,511	63,959	266,965	408,797	N/A
3/31/2019	2,097,224	135,192	194,365	328,479	N/A
12/31/2018	1,780,976	110,414	221,992	336,742	N/A
9/30/2018	1,769,726	140,738	225,190	328,658	N/A
6/30/2018	1,772,125	120,339	N/A	343,761	N/A
3/31/2018	1,770,531	186,886	N/A	377,854	N/A
12/31/2017	1,785,773	190,172	N/A	376,566	N/A
9/30/2017	1,762,667	163,457	N/A	316,619	N/A
6/30/2017	1,746,286	160,202	N/A	285,157	N/A
3/31/2017	1,732,051	114,940	N/A	261,363	N/A
12/31/2016	1,729,967	132,194	N/A	-8,176	N/A
9/30/2016	1,754,130	150,081	N/A	42,293	N/A
6/30/2016	1,795,088	155,110	N/A	57,618	N/A
3/31/2016	1,807,378	80,166	N/A	25,491	N/A
12/31/2015	1,831,096	-111,874	N/A	203,553	N/A
9/30/2015	1,830,521	-152,827	N/A	192,836	N/A
6/30/2015	1,812,971	-154,591	N/A	189,123	N/A
3/31/2015	1,777,824	-145,775	N/A	182,517	N/A
12/31/2014	1,744,795	75,405	N/A	N/A	N/A
9/30/2014	1,714,694	103,390	N/A	240,094	N/A
6/30/2014	1,692,531	110,981	N/A	N/A	N/A
3/31/2014	1,691,685	106,658	N/A	148,335	N/A
12/31/2013	1,655,033	103,330	N/A	N/A	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di TAK ( 12.2% all'anno) è superiore al tasso di risparmio ( 2.6% ).

Guadagni vs Mercato: Si prevede che gli utili di TAK ( 12.2% all'anno) cresceranno più lentamente rispetto al mercato US ( 15.4% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di TAK cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di TAK ( 0.9% all'anno) crescerà più lentamente rispetto al mercato US ( 9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di TAK ( 0.9% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di TAK sarà basso tra 3 anni ( 4.1 %).

Takeda Pharmaceutical Crescita futura

Future criteri di controllo 1/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Takeda Pharmaceutical Company Limited Raises Earnings Guidance for the Full Year 2024

Takeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024

Takeda Pharmaceutical Company Limited Revises Earnings Guidance for the Fiscal Year Ending March 31, 2024

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Recent updates

Takeda Pharmaceutical Company Limited to Report Q3, 2025 Results on Jan 30, 2025

Takeda Pharmaceutical Company Limited Raises Earnings Guidance for the Full Year 2024

Takeda Pharmaceuticals: An Interesting Option For Income Investors

Takeda Receives Approval from the Japanese Ministry of Health, Labour and Welfare to Manufacture and Market Fruquintinib for Previously Treated Colorectal Cancer

Takeda Receives European Commission Approval for ADZYNMA®

Corza Medical Inc. completed the acquisition of TachoSil manufacturing operations in Linz, Austria. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)

Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

Takeda Announces Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

Takeda Announces Phase 3 Topline Results for Soticlestat in Patients with Dravet Syndrome and Lennox-Gastaut Syndrome

Takeda: Strong Growth Catalysts And Maturing Pipeline Continue To Limit Downside Risk

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon

Takeda Receives Positive Chmp Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease

Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited (TSE:4502).

Takeda Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2024

Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (Tak-079), A Potential Best-In-Class Anti-Cd38 Monoclonal Antibody, for Primary Immune Thrombocytopenia

Takeda Pharmaceutical Company: Attractive Stock But Needs To Grow Net Profits

FDA Approves Takeda's EOHILIA (budesonide Oral Suspension)

Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024

Takeda Pharmaceutical Company Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024

Takeda Pharmaceutical Company Limited Announces Chief Financial Officer Succession, Effective April 1, 2024

Takeda's Gammard Liquidid®? Approves by U.S. Fda for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

Takeda Announces U.S. Food and Drug Administration Approves Hyqvia® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]

Takeda Pharmaceutical Company Limited to Report Q2, 2025 Results on Oct 31, 2024

Takeda Receives Positive Chmp Opinion for Hyqvia as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

The European Commission Approves Label Update for Takhzyro®? (Lanadelumab), Expanding Its Use to A Broader Group of Paediatric Patients with Recurrent Attacks of Hereditary Angioedema (Hae)

U.S. Fda Approves Takeda's Adzynma (Adamts13, Recombinant-Krhn) as the First and Only Recombinant Adamts13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombotic Thrombocytopenic Purpura

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

Takeda Pharmaceutical Company Limited Announces Late-Breaking Data from Phase 2B Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis At American College of Rheumatology Convergence Annual Meeting

Takeda Pharmaceutical Company Limited Revises Earnings Guidance for the Fiscal Year Ending March 31, 2024

Takeda Pharmaceutical Company Limited Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on December 1, 2023 and Provides Year-End Dividend Guidance for the Year Ending March 31, 2024

Takeda: Why I'm Staying Bearish On This Generic Drug Dividend Play

Takeda Pharmaceutical Company Limited Announces European Commission Approves ADCETRIS (Brentuximab Vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

Takeda Pharmaceutical Company Limited Announces Phase 3 ADMIRE-CD II Study

Takeda Pharmaceutical Company Limited to Report Q3, 2024 Results on Feb 01, 2024

Takeda Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

Takeda Pharmaceutical Company Limited Announces U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

Takeda Announces Approval of CUVITRU Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda Receives Positive CHMP Opinion Recommending Approval of Lanadelumab for Routine Prevention of Recurrent Attacks of Hereditary Angioedema in Patients Aged 2 Years and Older

Takeda Announces FDA Acceptance of NDA Resubmission of Tak-721 (Budesonide Oral Suspension) for the Short-Term Treatment of Eosinophilic Esophagitis

Takeda Pharmaceutical Company Limited Announces FDA Acceptance of BLA for Subcutaneous Administration of ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease

Takeda Announces Positive Topline Results from Phase 2b Study Evaluating TAK-279, a highly selective oral TYK2 Inhibitor, for the Treatment of Active Psoriatic Arthritis

Takeda: Innovative But Volatile, Fairly Priced For The Risk (Downgrade)

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Takeda Pharmaceutical Company Limited Announces Board Changes

Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy at PNS Annual Meeting

Takeda: Upside Case Strengthening, Looking To 15x Earnings

HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

Takeda Pharmaceutical Company and Eli Lilly and Company Provides Update on Class Action

Takeda Pharmaceutical Company Limited Proposes Dividend

Takeda Pharmaceutical Company Limited to Report Q2, 2024 Results on Oct 26, 2023

Takeda Announces S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Fiscal Year 2023

Takeda Pharmaceutical Company Limited Provides Dividend Guidance for the Fiscal Year 2023

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita